Table 2.
Treatment | 45 yo Patient % (Nb) |
75 yo Fit Patient % (Nb; p *) |
75 yo Unfit Patient % (Nb; p **) |
---|---|---|---|
Case i (IIb) | |||
Radiochemotherapy +/− surgery | 59 (69) | 64 (75; p = 0.33) | 47 (55; p = 0.03) |
Radiotherapy alone | 2 (2) | 2 (2; p = 1) | 20 (23, p < 0.001) |
Chemotherapy then radiochemotherapy | 7 (8) | 6 (7, p = 1) | 4 (5, p = 0.57) |
Chemotherapy then surgery | 8 (9) | 3 (4, p = 0.25) | 3 (4, p = 0.25) |
Surgery alone | 5 (6) | 3 (4; p = 0.75) | 3 (4; p = 0.75) |
Other | 19 (23) | 22 (25; p = 0.87) | 22 (26; p = 0.75) |
Case ii (IVa) | |||
Radiochemotherapy +/− surgery | 62 (72) | 59 (69; p = 0.71) | 35 (41; p < 0.001) |
Radiotherapy alone | 2 (2) | 1 (1; p = 1) | 20 (23; p < 0.001) |
Chemotherapy then radiochemotherapy | 17 (20) | 15 (17; p = 0.72) | 10 (12; p = 0.13) |
Chemotherapy then surgery | 3 (4) | 1 (1; p = 0.37) | 3 (3; p = 0.72) |
Supportive care only | 0 | 0 | 6 (7; p = 0.01) |
Other | 16 (17) | 25 (27; p = 0.13) | 26 (31; p = 0.03) |
Case iii (IVb) | |||
Chemotherapy doublet with platinum | 60 (70) | 55 (64; p = 0.51) | 36 (42; p = 0.001) |
Other chemotherapy +/− radiochemotherapy | 12 (15) | 15 (19; p = 0.58) | 23 (26; p = 0.08) |
Bevacizumab | 42 (49) | 33 (39; p = 0.22) | 12 (15; p < 0.001) |
Radiochemotherapy | 10 (12) | 10 (12; p = 1) | 11 (13; p = 1) |
Supportive care only | 1 (1) | 4 (5; p = 0.21) | 15 (17; p < 0.001) |
Other | 16 (19) | 15 (17; p = 0.86) | 16 (19; p = 1) |
Case iv (metastatic recurrence) | |||
Chemotherapy | 83 (97) | 78 (91; p = 0.28) | 54 (63; p < 0.001) |
Bevacizumab | 54 (63) | 44 (52; p = 0.19) | 18 (21; p < 0.001) |
Chemotherapy if symptomatic | 8 (9) | 11 (13; p = 0.5) | 18 (21; p = 0.001) |
Supportive care only | 0 | 2 (2; p = 0.5) | 19 (22; p < 0.001) |
Others | 9 (11) | 9 (11; p = 1) | 9 (11; p = 1) |
p < 0.05 are in bold. yo: year-old; * Comparison between 75 year-old fit patient and 45 year-old patient; ** Comparison between 75 year-old unfit patient and 45 year-old patient.